Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

A qualitative exploration of race-based differences in social support needs of diverse women with breast cancer on adjuvant therapy.

Paladino AJ, Anderson JN, Graff JC, Krukowski RA, Blue R, Jones TN, Buzaglo J, Kocak M, Vidal GA, Graetz I.

Psychooncology. 2019 Mar;28(3):570-576. doi: 10.1002/pon.4979. Epub 2019 Feb 5.

PMID:
30636189
2.

Sistas Taking a Stand for Breast Cancer Research (STAR) Study: A Community-Based Participatory Genetic Research Study to Enhance Participation and Breast Cancer Equity among African American Women in Memphis, TN.

Smith A, Vidal GA, Pritchard E, Blue R, Martin MY, Rice LJ, Brown G, Starlard-Davenport A.

Int J Environ Res Public Health. 2018 Dec 18;15(12). pii: E2899. doi: 10.3390/ijerph15122899.

3.

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.

Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang J, Xiao N, Greil R, Rinnerthaler G, Gampenrieder SP, Heimberger AB, Berry DA, Barker A, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Magee D, Miglarese MR, Famulok M, Mayer G, Spetzler D.

Nat Commun. 2018 Mar 23;9(1):1219. doi: 10.1038/s41467-018-03631-z.

4.

Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.

Graetz I, McKillop CN, Stepanski E, Vidal GA, Anderson JN, Schwartzberg LS.

J Cancer Surviv. 2018 Aug;12(4):431-440. doi: 10.1007/s11764-018-0682-z. Epub 2018 Feb 28.

PMID:
29492753
5.

Phase I Trial of Everolimus and Capecitabine in Metastatic HER2- Breast Cancer.

Vidal GA, Chen M, Sheth S, Svahn T, Guardino E.

Clin Breast Cancer. 2017 Oct;17(6):418-426. doi: 10.1016/j.clbc.2017.03.003. Epub 2017 Mar 16.

PMID:
28385537
6.

Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer.

Vontela N, Koduri V, Schwartzberg LS, Vidal GA.

J Natl Compr Canc Netw. 2017 Mar;15(3):284-287.

PMID:
28275030
8.

Clinical Outcomes among Transferred Children with Ischemic and Hemorrhagic Strokes in the Nationwide Inpatient Sample.

Adil MM, Vidal GA, Beslow LA.

J Stroke Cerebrovasc Dis. 2016 Nov;25(11):2594-2602. doi: 10.1016/j.jstrokecerebrovasdis.2016.06.043. Epub 2016 Jul 21.

PMID:
27453219
9.

Description of a novel telemedicine-enabled comprehensive system of care: drip and ship plus drip and keep within a system of stroke care delivery.

Commiskey P, Afshinnik A, Cothren E, Gropen T, Iwuchukwu I, Jennings B, McGrade HC, Mora-Guillot J, Sabharwal V, Vidal GA, Zweifler RM, Gaines K.

J Telemed Telecare. 2017 Apr;23(3):428-436. doi: 10.1177/1357633X16637967. Epub 2016 Mar 16.

PMID:
26989161
10.

Outcomes of transient ischemic attack in maintenance dialysis patients and those with chronic kidney disease.

Saeed F, Adil MM, Vidal GA, Piracha BH, Nahab F, Khan AS, Navaneethan SD.

Nephrol Dial Transplant. 2016 Jan;31(1):128-32. doi: 10.1093/ndt/gfv246. Epub 2015 Jul 9.

PMID:
26160895
11.

Acute renal failure is associated with higher death and disability in patients with acute ischemic stroke: analysis of nationwide inpatient sample.

Saeed F, Adil MM, Khursheed F, Daimee UA, Branch LA Jr, Vidal GA, Qureshi AI.

Stroke. 2014 May;45(5):1478-80. doi: 10.1161/STROKEAHA.114.004672. Epub 2014 Mar 11.

PMID:
24619397
12.

The change in the atrial fibrillation type as a prognosis marker in a community study: long-term data from AFBAR (Atrial Fibrillation in the BARbanza) study.

Vidal-Perez R, Otero-Raviña F, Lado-López M, Turrado-Turrado V, Rodríguez-Moldes E, Gómez-Vázquez JL, de Frutos-de Marcos C, de Blas-Abad P, Besada-Gesto R, Gonzalez-Juanatey JR; BARBANZA Investigators.

Int J Cardiol. 2013 Oct 3;168(3):2146-52. doi: 10.1016/j.ijcard.2013.01.261. Epub 2013 Feb 26.

PMID:
23452888
13.

A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities.

Vidal GA, Clark DE, Marrero L, Jones FE.

Oncogene. 2007 Jan 18;26(3):462-6. Epub 2006 Jul 10.

PMID:
16832345
14.

The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.

Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM, Jones FE.

Cancer Res. 2006 Jun 15;66(12):6412-20.

15.

Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.

Vidal GA, Naresh A, Marrero L, Jones FE.

J Biol Chem. 2005 May 20;280(20):19777-83. Epub 2005 Mar 3.

16.

The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.

Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE.

J Cell Biol. 2004 Nov 8;167(3):469-78.

Supplemental Content

Loading ...
Support Center